INDEX TO VOLUME 171

Author Index

Aaby, P., 506
Abd-Alla, M., 645
Abe, S., 1539
Acar, J. F., 1646
Adams, L. B., 400
Adams, R., 1545
Addiss, D. G., 755
Adler, M., S118
Adler, S. P., 26
Aguero, B., 1309
Ahlers, C. M., 1628
Ahmann, D. R., 1675
AIDS Clinical Trials Group 199 Study Team, 297
AIDS Clinical Trials Group, 1431
Akagawa, G., 1539
Akutsu, N., 425
Albert, M. J., 122, 1653
Alberti, A., 760
Alden, M. B., 204
Alling, D. W., 447
Alonso, P. L., 1360
Altamirano, M., 1034
Alter, H. J., 768
Alvord, W. G., 145
Ambrose, M. R., 851
Ampel, N. M., 1675
Andersen, B. R., 68
Anderson, B. D., 1152
Anderson, E. C., 1075
Anderson, E. L., 1595
Anderson, K. W., 1159
Anderson, L. J., 1
Anderson, R. E., S118, S123, S131
Andersson, J., 376
Ando, T., 1497
André, F. E., S33, S44
Andreu, A., 1237
Andrieu, J.-M., 523
Andriole, V. T., 1553
Anegon, I., 232
Antolín, E., 1360
Anzala, O. A., 686
Apolonio, E. G., 829
Arakawa, T., 1309
Arankalle, V. A., 447
Araujo, E. N., 652
Armien, B., 1022
Armstrong, G. D., 1042
Arruda, E., 1329
Artenstein, A. W., 805
Arvin, A. M., 13
Asano, T., 425
Asano, Y., 273
Ashkenazi, S., 1244
Ashley, R., 33
Auclair, F., 1042
Ayoub, A., 1504
Ayuk, J., 1380
Azadian, B., 511
Bachmeyer, C., 1190
Baenziger, J., 1343
Bagasra, O., 190
Bagley, M. R., S70
Bai, G. H., 954
Bailey, T. C., 1006
Bailey-Farchione, A., 1081
Baird, J. K., 1678
Baken, L. A., 429
Bakker-Woudenberg, I. A. J. M., 385, 938
Bakshi, K. K., 1159
Balcarek, K. B., S70
Baldanti, F., 1603
Baldelli, F., 1448
Balish, E., 1664
Ballaré, M., 672
Ballet, J. J., 256
Ballou, W. R., 1576
Baltch, A. L., 406
Bancroft, W. H., S53
Banerjee, K., 447
Bannerman, T. L., 614
Baralle, F., 760
Barbour, M. L., 93
Barnes, D., 837
Barnes, D. M., 890
Barnum, G., 1081
Baron, R., 1053
Barr, C. E., 190
Barrett, N., 437
Barthold, S. W., 1368, 1380
Basanta, G., 1045
Basri, H., 1678
Bassetti, D., 1317
Bassiakos, Y., 297
Batts, D., 297
Bean, N. H., 371
Beauvais, B., 245
Becker, S., 584
Behets, F. M.-T., 451
Bélec, L., 1615
Bell, G. L., 724
Belsey, E., 1611
Belshe, R. B., 1595
Bemelmans, M., 393
Bendel, C. M., 1660
Benedetti, I., 514
Benedetti, L., 273
Benne, C. A., 335
Bennett, J., 506
Berens, R. L., 984
Bergen, R., 13
Bergeron-Lynn, G., 782
Bergmans, A. M. C., 916
Berman, J., 751
Berman, J. W., 493
Bertoncelli, M. C., 672
Bertram, M., 225
Besen, G., 782
Besh, S., 997
Best, A. M., 26
Beutler, B., 570
Bhattacharya, S. K., 759
Bijlmer, R., 229
Bilello, J. A., 546
Bilello, P. A., 546
Binn, L. N., S53, S61
Binsztein, N., 1045
Biron, K. K., 576
Bironneau, E., 232
Birx, D. L., 1420, 805
Bischofberger, N., 1338
Bisno, A. L., 601
Bistoni, F., 1279, 1448
Blake, M. S., 593
Blanchard, C., 1042
Blanton, R. E., 416
Blatt, S. P., 837
Blattner, W. A., 693, 1022
Blok, W. L., 393
Body, G., 1384
Boner, W., 1461
Bonnez, W., 1081
Bonora, S., 1317
Bopp, C. A., 122
Boppana, S. B., 1115, 182
Borleffs, J. C. C., 1632
Boscia, J., S53
Boswell, R. N., 837
Boucher, C. A. B., 1166, 1411
Boufassa, F., 1190
Bóveda, J. L., 472
Bowden, R. A., 1545
Boyle, M. D. P., 85, 1643
Boyle, T. R., 1329
Bradley, J. E., 652
Braga, C., 997
Brasseur, P., 256
Braun, D. K., 1122, 1351
Breiman, R. F., 864, 885, 1491
Britt, W. J., 18, 182, 1115
Broder, S., 1152, 1180
Brodine, S. K., 693
Brokstad, K. A., 198, 1072
Broome, C. V., 632
Broström, C., 509
Brouwer, E., 335
Brown, A., 1074
Brown, A. J. L., 45
Brown, B. A., 747
Brown, C. S., 710
Brown, D., 697, 845
Brown, J. M., 1599
Brown, K. A., 1334
Brusuelas, K., 1650
Bruzzese, E., 976
Bryan, R. T., 1375
Bucko-Krasnicka, B., 837
Bucquet, D., 1190
Buhles, W., 1431
Buis, J., 26
Bulger, P. A., 909, 1049
Bulkow, L. R., 676, 1065
Buller, R. S., 1006
Burchett, B. M., 701
Burger, R. A., S93
Burke, A., S53
Burke, D. S., 805
Burman, L. G., 128
Burnie, J., 1668
Burns, B. A., 1107
Burr, D. H., 212
Busch, D. F., 1431
Busch, H., 683
Butler, J. C., 864, 885
Buurman, W. A., 393, 739, 1250
Bwayo, J. J., 686
Byrnes, V. W., 1159
Caiaffa, W. T., 1196
Calamari, S. R., 1636
Calandra, G. B., 1159
Calandra, T., 639
Caldwell, B., 689
Calvopiña, M. H., 652
Cameron, D. N., 122
Campbell, C. C., 489
Campbell, G. L., 356
Campo, R. E., 601
Canani, R. B., 976
Canva-Delcambre, V., 743
Caparon, M. G., 871
Caprioli, A., 514
Cararach, V., 1360
Carella, A. V., 768
Carew, A., 515
Carey, J. C., 1475
Carlone, G. M., 632
Carlson, S., 1660
Carman, W. F., 1461
Caron, F., 106
Carpenter, A., 153
Carr, J. K., 805
Carré, N., 1190
Carrigan, D. R., 273
Carruba, G., 967
Cartter, M. L., 1371
Casarin, C., 760
Casola, A., 976
Casper, J. T., 1090
Cassatella, M., 1317
Cassiday, P., 1650
Cassone, A., 967
Castagna, A., 1603
Castillo, L. C., 1022

Catrenich, C. E., 459
Ceesay, S. J., 632
Cenci, E., 1279
Chadha, M. S., 447
Chakkalath, H. R., 1302
Chambers, H. F., 897
Chan, C.-Y., 443
Chan, M. C. K., 1076
Chandrashekar, R., 1586
Chang, M.-H., 776
Chao, C. C., 516
Chapman, B., 1628
Chapman, L., 864
Chappell, C. L., 1071
Chaturvedi, S., 320
Chavez, E., 782
Cheek, J. E., 864
Cheeseman, S. H., 537
Cheevers, W. P., 328
Chemello, L., 760
Chen, D.-S., 776
Chen, J.-H., 732
Chen, M., 1356
Chen, P.-J., 776
Chernoff, D., 1343
Chesney, M., 1343
Chiang, E. C., 1038
Childs, J. E., 864
Chimba, R. M., 371
Chinookoswong, N., 1528
Chintu, C., 1636
Chirgwin, K. D., 170
Choi, A., 1081
Chokekijchai, S., 1152
Chong, K.-T., 61
Chou, S., 576
Chretien, J., 1347
Christ, G. J., 493
Christen, H.-J., 476
Christopherson, C., 1411
Churchill, W. H., 1002
Cicirello, H. G., 1497
Ciesielski, C. A., 961
Cinque, P., 1603
Cinto, R., 1045
Claeys, H., 1380
Clark, I. A., 1068
Clark, N. M., 1122
Cleland, A., 45
Clemens, J., 1653
Clemens, R., S44
Clement, C., 469
Clements, M. L., 1107, 1623
Cloud, G. A., 1675
Cockerill, F. R., III, 240
Cohen, B. J., 710
Cohen, J., 153
Cohen, J. C., 1576
Cohen, M. S., 451
Cohn, S., 1196
Coleman, P. J., 54
Coles, C., 93
Coles, F. B., 732
Collart, J.-P., 1380
Collier, A. C., 33, 1018
Collis, P., 1411
Colombel, J. F., 743
Comby, E., 256
Concia, E., 1317
Connell, H., 625
Connor, J. D., 1431
Conrad, P. A., 505
Conway, B. P., 462
Cook, D. R., 984
Cookson, B., 511
Cookson, S., 465
Cooley, T. P., 1438
Coombs, R. W., 305, 1018, 1172
Cooper, J. D., 1006
Coque, T. M., 1223
Corey, L., 33, 521, 1018, 1081
Costa, J., 1360
Cot, S., 1069
Cotch, M. F., 1475
Cotty, F., 1384
Coughlin, R. T., 909, 1049
Coutinho, R. A., 531, 811
Cowden, W. B., 1068
Cox, J. H., 1420
Cox, R. J., 1072, 198
Cox, S., 297
Cravioto, A., 465
Crook, D. W. M., 93, 1075
Cross, A., S118, S123, S131
Crowley, R. W., 273
Crumpacker, C. S., 1002, 1172, 1628
Cuevas, L. E., 728
Cundy, K., 788
Curiel, T. J., 984
Curtis, K. C., 1586
Cushion, N. B., 614
Cytomegalovirus Cooperative Study Group, 1431
Daily, P. J., 762
Dale, J. B., 1038
Dales, L., 1053
Dallabetta, G., 451
Dalton, C., 864
Dando, S., 1628
Danner, S. A., 1166, 1411
Dante, S., 909
Dao, T., 232
D'Aquila, R. T., 1172
Darnell, M. E. R., 440
Das, B. C., 254
Das, D. K., 254
daSilva, A. J., 1375
da Silva Telles, M. A., 237
Davidson, M., S50, 1065
Davies, J., 1522
Davis, D. v. R., 909
Davis, G. L., 281
Davis, J. C., 1067
Dawson, J. E., 1266
Dayhoff, D. E., 805
de Almeida Filho, P. J., 997
De Beenhouwer, H., 1380
de Bel, C. E., 1057
De Bernardis, F., 967
Decker, C. F., 1406
De Clercq, E., 782
De Cock, K. M., 502
de Courten, M. P., 762
DeFraites, R. F., S53, S61, 1074, 1266
De Groote, D., 232
De Groote, M. A., 1375
DeGruttola, V., 305
de Haas, P. E. W., 1504
de Jong, D., 1411
de Jong, I. W., 1640
Delaney, A., 1034
Delem, A. D., S61
Delgado, K. L., 1675
De Maddalena, C., 672
Demeter, L. M., 297, 1081
de Moraes-Pinto, M. I., 1076
de Neeling, H., 1504
Dennis, D. T., 356
Dentener, M. A., 739, 1250
Derkx, B., 229
DeRouen, T., 33
Derouin, F., 245
Descamps, P., 1384
Detels, R., 829
Deveau, C., 1190
Devlin, R. B., 584
Dewar, A., 113
de Wolf, F., 811
Dezube, B. J., 1628
D'Hondt, E., S40, S53
Dhumeaux, D., 1607
Diehl, V., 225
Diese, M., 503
Dietrich, O., 683
Dietze, R., 751
Dimock, K. A., 755
Dinari, G., 1244
Di Perri, G., 1317
Di Perri, I. G., 1317
Dolan, M. J., 837
Domschke, W., 683
Donohue-Rolfe, A., 721
Donta, S. T., 721
Dorner, F., 437
Douglas, S. A., 493
Dowell, S. F., 1497
Dowling, A., 177
Drew, W. L., 1431, 788
Driessen, C., 486
Drobniewski, F., 515
Dropulic, L. K., 930
Drusano, G. L., 546
Dryer, D., 614
Duan, S.-C., 54
Dudley, M. N., S99
Duliege, A.-M., 1343
Dunkle, L. M., S118, S123, S131
Dunne, A., 1081
DuPont, H. L., 1636
Durr, S., 1159
Durry, E., 1672
Dusi, S., 1317
Dutch AIDS Treatment Group, 1632
Duval, J., 1607
Dwyer, D. M., 1497, 513
Eaton, K. A., 459
Eberhard, M. L., 755
Eder, G., 437
Edlind, T. D., 204
Edlund, K., 1026
Eerola, E., 1060
Egan, J. E., S53
Egan, M. A., 1623
Ehrenfeld, E., 845
Ehresmann, K. R., 679
Ehrett, S., 161
Eibl, M. M., 437
Eickhoff, T., S73
Eiffert, H., 476
Eisenberg, E., 1122
Elbeik, T., 1343
Eldred, L. J., 930
El-Farra, N. S., S15
Eling, W., 1069
El-Kersh, T. A., 483
Ellner, J. J., 1066
Elson, L. H., 652
Emerson, S. U., S40, 447
Emini, E. A., 1159
Emmons, W. W., 1406
Englund, J. A., 99
Enssle, K.-H., 1279
Epstein, M. P., 1258
Erice, A., 537, 576
Erikson, L., S53
Eschenbach, D. A. for the Vaginal Infection and Prematurity Study Group, 1475
Eskola, J., 1075
Espy, M., 1010
Essex, M., 503
Esteban, F., 472
Estes, M. K., 566
Ettestad, P. J., 356
Ettinger, N. A., 1006
Evander, M., 1026
Evans, T. J., 153
Evins, G. M., 122
Facklam, R. R., 885, 1491
Fahey, J. L., 1628
Fairchok, M., 954
Falla, T. J., 1075
Färkkilä, M., 1692
Farmer, J. J., III, 122
Farthing, M., 515
Farzadegan, H., 312, 797, 822
Faulhaber, J., 683
Favennec, L., 256
Fay, J., 18
Feder, H. M., 1371
Feeley, J. C., 122
Feighner, B. H., S61
Feinberg, M., 1343

Feldman, A. R., 1545
Felix, D. H., 1122
Fennell, C. L., 717, 1237
Fernández-Rodríguez, M., 967
Ferrazoli, L., 237
Ferreira, O. C., 237
Fessel, J., 177
Fields, P. I., 122
Fikrig, E., 1368
Fine, P. E. M., 502
Finne, J., 1481
Fischer, M. B., 437
Fischl, M., 297
Fiscus, S. A., 305
Fish, D., 1049
Fishbein, D. B., 1266
Fisher, P. E., 788
Fitzgerald, M. A., 1065
Flaherty, J., 788
Flavell, R. A., 1368
Fleming, P. L., 961
Flexner, C., 1628
Flock, J.-I., 1230
Flomenberg, P., 1090
Flores-Aguilar, M., 782
Folks, T. M., 1210
Follansbee, S., S131, 1431
Follis, K. E., 1338
Fontana, M., 976
Fornoff, J. E. R., 1006
Fortuny, A., 1360
Foxman, B., 1514
Frame, P., 320
Francisci, D., 1448
Francot, G. J. M., 739
Frank, T. S., 1122
Franke, M. A., 406
Freedman, D. O., 997
Freeman, T. M., 837
Freeman, W. R., 782
Freifeld, A. G., 1031
Frey, T., 1691
Friedland, I. R., 161
Frieling, J. T. M., 469
Frommel, D., 1504
Froon, A. H. M., 739, 1250
Fryauff, D. J., 1678
Fukuda, K., 1022
Fung, M. S. C., 1203
Furione, M., 1603
Furtado, A. F., 997
Furuta, Y., 194
Gage, K., 864
Galai, N., 768
Galgiani, J. N., 1672, 1675
Galli, M., 672
Gallin, J. I., 145
Gallo, R. C., 273
Gambel, J. M., 1074
Gangadharam, P. R. J., 68
Gangan, P. A., 782
Gaudebout, C., 1070
Gaudreault-Keener, M., 1006
Gauduin, M.-C., 1203
Gaywee, J., 805
Geheb, H., 297
Gekker, G., 516
Genese, C. A., 356
Genta, R. M., 1636
Gentry, M. J., 350
Gentsch, J. R., 1497
George, L. K., 701
Gerardy-Schahn, R., 1481
Gerber, M. A., 724, 1371
Gerotto, M., 760
Gershon, A., S73
Gertig, D. M., 290
Geuijen, C. A. W., 924
Ghassemi, M., 68
Giang, T. T., 552
Gibbs, R. S., 1475
Gilligan, P. H., 890
Girard, W., 747
Girmenia, C., 967
Gish, R. G., 281
Giusti, R., 1022
Glass, R. I., 1497
Glauser, M. P., 639
Glezen, W. P., 99
Glimcher, L. H., 362, 1302
Glutzer, E., 788
Godard, A., 232
Goeman, J., 1611
Goering, R. V., 1646
Göhler, R., 1159
Golbeck, A. L., 693
Goldman, M., 229
Goldmann, D. A., 220
Goldstein, F. W., 1646
Gómez-Jiménez, J., 472
Goodgame, R. W., 1071
Goodyer, P., 1042
Gopalkrishna, V., 254
Gordon, D. L., 186
Gordon, D. M., 1576
Gordon, M. A., 406
Gormus, B., 503
Gosset, P., 743
Goudsmit, J., 811
Govindarajan, S., S40
Gracia, F. I., 1022
Graham, B. S., 1468
Graham, N. M. H., 1196
Graninger, W., 1078
Grant, R., 1338
Gratacós, E., 1360
Gravallese, E. M., 362
Grayston, J. T., 736
Green, D. B., 1022
Greenberg, S., 570
Greenough, T. C., 537
Greenwood, B. M., 632
Greisberger, C., 297
Grésenguet, G., 1615
Greve, J. W. M., 1250
Grew, M. I., S15
Griffin, P. M., 371
Griffith, D. E., 747
Griffiths, J., 1069
Grifo, J. A., 1657
Grimm, M. B., 679
Grogl, M., 751
Groothedde, J.-W., 916
Grossman, D. A., 212
Groves, C., 1497
Gruber, W. C., 1468
Grusby, M. J., 1302
Guarino, A., 976
Guderian, R. H., 652
Guebrexabher, H., 1504
Guerrant, R. L., 8
Guers, L. D., 465
Gun, Z.-L., 54
Gupta, P., 305
Gust, I. D., 290
Gustafsson, Å., 1026
Gutmann, L., 106
Gwaltney, J. M., Jr., 1329
Haaheim, L. R., 198, 1072
Hack, C. E., 1640
Hackett, C. S., 1595
Hahn, A., 639
Hahn, B. L., 1289
Haley, R. W., 614
Hall, D., 537
Hall, J. A., 462
Hall, S. L., 1107
Hallahan, D., 1081
Haller, O., 705
Hamed, K., 432
Hamilton, H. A., 451
Hamilton, J. D., 701
Hanai, N., 1481
Handsfield, H. H., 33
Handy, J., 584
Hanff, P., 1002
Hannigan, J., 788
Hanrieder, K., 1461
Hansen, E., 161
Hansen, K. K., 1689
Hanski, E., 871
Hanson, C. A., 1351
Hardy, W. D., S131
Hariprashad, J., 1309
Harmsen, M., 335
Harris, D. O., 1107
Harrison, L. H., 513
Hart, C. A., 728, 1076
Harvey, E., 45
Harvey, J., 99
Hasilik, A., 683
Hassett, J., S123
Hatcher, V. B., 493
Hattori, N., 1381
Hauser, P., 1576
Havlir, D., 537
Hawkins, E. P., 342
Hayden, F. G., 1329
Häyrinen, J., 1481
Hayward, A. R., 1383
Hazenbos, W. L. W., 924
He, Y., 829
Hedberg, C. W., 679
Hedman, K., 710
Heersma, H., 1504
Heese, C., 683
Hegerich, P. A., 805
Heilman, C. A., 1
Heimdahl, A., 1230
Hemming, V. G., 440
Hempfling, S. H., 26
Henderson, F. W., 584, 890
Hendrix, C. W., 837, 1688
Heneine, W., 1210
Hennig, C., 1317
Hensley, R. E., 837
Hepburn, A., S44
Heppner, D. G., 1576
Herbertz, A., 225
Hermans, P. W. M., 1504
Hetherington, S. V., 851
Hickey, S. M., 161
Hienz, S. A., 1230
Hildebrand, C. S., 1159
Hill, A., 1166
Hill, B., 1491
Hill, J., S53
Hilliard, J. K., 1031, 1139
Hillier, S. L., 1237, 1475
Hino, S., 1455
Hipp, S. S., 732
Hirschfeld, S., 761
Hirst, H. M., 1438
Hirv, K., 486
Hlavacova, B., 1491
Hodgetts, S., 1668
Hoepelman, A. I. M., 1632
Hoffman, I. F., 451
Hoffman, S. L., 1569, 1678
Hoffstedt, B., 1159
Hofmann, B., 1689
Hofmann, J., 885
Hogervorst, E., 811
Hoke, C. H., Jr., S53, S61, 1074
Holder, P. K., 632
Hollingdale, M., 1576
Hollinger, F. B., S1, S73, 1620
Holloway, M., 1081
Holmes, E., 1461
Holmes, E. C., 45
Holmes, K. K., 429, 455
Holton, D., 686
Hooton, T. M., 717
Hoover, D. R., 829
Hopkins, W. J., 462
Horal, P., 194
Hostetter, M. K., 1660
Hseih, K.-H., 776
Hsu, H.-Y., 776
Hu, D. J., 961
Hu, R., 1258
Hu, S., 516
Huang, E. H., 263
Huang, H., 493
Huda, S., 1653
Hufert, F. T., 705

Hughes, W. T., 1295
Hullinger, G. A., 328
Humbert, G., 106
Humphrey, C. D., 1497
Hutcheson, R. H., 1672
Hutchinson, G., 511
Hwang, S.-J., 443
Hyams, K. C., 693
Igbagiri, F. P., 1076
Iha, S., 1455
Ijzerman, E. P. F., 216
Ilstrup, D. M., 1014
Ilunga, M., 503
Imai, J., 559
Ingrand, D., 1166
Invernizzi, F., 672
Isono, K., 425
Ito, S. I., 693
Jaccard, A., 245
Jackson, R., 1053
Jackson, T. F. H. G., 645
Jacobson, M. A., 1431
Jadand, C., 1190
Jaffe, H. S., 788
James, C., 788
Janoff, E. N., 1217
Jansen, P. M., 1640
Japour, A. J., 1172
Jennings, H., 1481
Jesudason, M. V., 759
Jia, X. Y., 845
Jiang, X., 566
Jiang, Z. D., 1636
Jiménez de Anta, M. T., 1360
Jin, Q., 1497
Jodal, U., 625
John, T. J., 759
Johnson, A., 1569
Johnson, A. P., 511
Johnson, B. J. B., 1266
Johnson, J. A., 513, 903
Johnson, J. L., 1066
Johnson, L. L., 249
Johnson, P. C., 566
Johnson, P. M., 1076
Johnson, S. A., 440
Johnson, V. A., S140, 1172
Jones, J. L., 961
Jones, T. J., 508
Jones-Carson, J., 1664
Jong, E. C., S73
Jonsson, M., 1026
Jonsson, R., 198
Jordan, M. C., 576
Jung, D., 1431
Jurriaans, S., 811
Kahn, J. O., 1172, 1343
Kain, K. C., 645
Kamahora, T., 1455
Kandun, N., 290
Kaneshima, H., 1599
Kanjarpane, D. D., S61
Kantor, F. S., 1368
Kaplan, J. E., 1022, 961
Kaplan, S. L., 342
Karabatsos, N., 1074
Karlsson, R., 1026
Karmam, M., 1611
Karron, R. A., 1107
Kartalija, M., 897, 948
Kasdan, P., 1628
Kashala, O., 503
Kaslow, R. A., 829
Kasongo, K., 503
Kasper, D. L., 879
Katamine, S., 1455
Katlama, C., 1166
Katouli, M., 128
Katzenstein, D. A., 305, 1072
Katzman, M., 305
Kaufman, L., 1672
Kaufmann, M., 511
Kay, B., 1653
Kazembe, P., 728
Keane, V., 489
Keay, S., 312
Kelly, P., 170, 515
Kennedy, D. J., 1595
Kennedy, M., 676
Kennedy, S., 1363
Kensil, C., 18
Kerr, J. S., 362
Kew, O. M., 1399
Khabbaz, R. F., 1022
Khan, A. S., 762
Khoury, C. A., 1334
Kieff, E., 1323
Kim, J. E., 1334
Kim, Y. S., 948, 1363
Kimes, M. H., S53
King, C. L., 416
Kirchner, H., 486
Kirkland, K. B., 1497
Kirste, G., 705
Kitchen, V., 1166
Kitzis, M.-D., 106
Kiviat, N. B., 429
Klassen, T. P., 1042
Klempner, M. S., 1258
Kligman, I., 1657
Kline, B. C., 240
Kluytmans, J. A. J. W., 216
Knight, D. A., 263
Knowler, W. C., 762
Kobayashi, S., 425
Kober, A., 1159
Koech, D., 1569
Koenig, S., 182
Koff, R. S., S19, S73
Kohara, M., 281, 1381
Kohno, T., 1528
Kojima, E., 1152
Kolberg, J. A., 281
Kolls, J. K., 400, 570
Kolsters, A. F. P., 1632
Komaroff, A. L., 273
Komatsu, K. K., 864
Komoda, H., 559
König, B., 607
König, W., 607
Koopmans, M. P. G., 1399
Koot, M., 531
Koren, H. S., 584
Kornfeld, H., 1559
Korvick, J. A., 1628
Koskiniemi, M., 1692
Kosorok, M. R., 429
Kostman, J. R., 204
Kotb, M., 74
Kotler, D. P., 552
Koup, R. A., 1203
Koutsky, L. A., 429
Kozal, M. J., 1072
Kraaijeveld, C. A., 335
Krahenbuhl, J. L., 400
Krajcikova, L., 1491
Krakowka, S., 459
Kramer, A. A., 182
Krause, D., 676
Krause, D. S., S61, S70, 676
Krause, P. J., 505, 1371
Krauss, M. R., S61
Krebs, J. W., 864
Kreisl, C., 1159
Kreiswirth, B., 74
Krieger, J. N., 1018
Kriesel, D., S118
Kritski, A., 237
Krohn, M. A., 1475
Krom, R. A. F., 1010, 1014
Krug, E. C., 984
Krugman, S., S50
Kruize, Y. C. M., 1683
Krutchkoff, D. J., 1122
Krzych, U., 1576
Ksiazek, T. G., 762, 864
Kucharzik, T., 683
Kuhns, D. B., 145
Kullberg, B.-J., 393
Kumah, S., 632
Künzi, M. S., 822
Kuo, C.-C., 736
Küpcü, Z., 437
Kuritzkes, D. R. for the ACTG 116B/117 Study Team, 1172
Kurniawan, A., 1683
Kuypers, J., 429
Kwok, S., 1411
LaChance, R., 1576
LaFon, S. W., 1295
Laga, M., 1611
Lakeman, F. D., 857
Lalezari, J. P., 788, 1431
Lammie, P. J., 755
Lamson, M., 537
Landmann, R., 639
Lang, D. R., 8
Lange, J. M. A., 1611
Langermans, J. A. M., 1057
Langlois, T. M., 1006
Larkin, C., 170
Larson-Keller, J. J., 1014
Lau, J. Y. N., 281
Lauder, I. J., 1620
Lazzarin, A., 1603
Leach, A., 632
Lederman, M. M., 1628
Lee, C.-Y., 776
Lee, S.-D., 443
Lee, S.-K., 429
Leedom, J., 297
Lehtonen, L., 1060
Lei, D., 570
Leikola, M., 1692
Leinonen, M., 479
Leitch, G. J., 1375
Leksana, B., 1678
Lemeland, J.-F., 106
Leslie, J. M., 930
Lesmana, M., 212
Lesser, M. L., 992
Levenstein, M. J., 1545
Levin, M. J., 1383
Levin, M. M., 903
Levine, M. M., 465
Levine, P. H., 1022
Levy, R., 523
Li, Z., 416
Licate, L. S., 416
Lieberman, D., 1274
Lillo, F., 1603
Limentani, S. A., 1258
Lin, H. J., 1620
Lindberg, A. A., 376
Linde, A., 1603
Lindh, M., 194
Lindsay, K. L., 281
Link, S., 639
Liomba, G., 451
Lior, H., 1042
Lipman, H. B., 885
Lipskaya, G. Y., 1399
LiPuma, J. J., 204
Liu, C.-B., 54
Ljunggren, K. K., 194
Lo, K.-J., 443
Lobet, Y., 1368
LoFaro, M. L., 305
Looareesuwan, S., 1078
Loomis, L. D., 1420
Losonsky, G. E., 903
Lottenberg, R., 85
Louie, A., 406
Loveday, C., 1411
Low, D. E., 74
Lowe-Bey, F. H., 1406
Lu, C.-L., 443
Lu, R.-H., 443
Lu, W., 523
Lucas, S. B., 502
Lügering, N., 683
Lule, G., 451
Luo, N., 515, 1636
Lusso, P., 273
Luthra, U. K., 254
Luzzi, I., 514
Lyter, D. W., 829
Ma, J., 909, 1049
Maat, A. W. P. M., 216
MacArthy, P. O., S53, S61

MacDonald, K. L., 679
Maciel, A., 997
MacKenzie, A., 1042
Mainardi, J.-L., 1646
Maia e Silva, M. C., 997
Mair, M., 204
Maizels, R. M., 1683
Makhene, M., 1107
Makin, K. M., 459
Malawista, S. E., 1380
Malde, M., 511
Maldonado, Y. A., 689
Manca, F., 1420
Mannhalter, J. W., 437
Manning, M. L., 26
Marchant, A., 229
Marchetti, C. M., 356
Margolick, J. B., 312, 822
Margolis, H. S., 54
Mårild, S., 625
Markham, R. B., 797
Marklund, B.-I., 625
Markovitz, D. M., 1122
Markowitz, J. S., 1302
Markowitz, L., 506
Marlink, R., 503
Marostenmaki, J., 1034
Marques, L. R. M., 237
Marrs, C. F., 1514
Marschner, I. C., 290
Martin, J. C., 788
Martín, M. C., 472
Martin, R., 153
Martin, R. R., S118
Martin, T. R., 134
Martino, P., 967
Masbar, S., 1678
Mascola, J. R., 805
Mason, C. M., 400
Mason, E. O., Jr., 342
Massari, F. E., 1159
Mastre, B., 1431
Masur, H., 1295
Mather, T. N., 1049
Mathewson, J. J., 1636
Matta, M., 1615
Matthews, R., 1668
Mattiacci, M. R., 1628
Matuschka, F.-R., 476
Maudgal, P. C., 782
Maupin, G. O., 864
Maynard, J. E., 290
Mayon-White, R. T., 93
Mboup, S., 1611
McBride, M., 1166
McCance, C., 489
McCarthy, W. F., 837
McCarty, M., 593
McCloud, B., 1258
McCracken, G. H., Jr., 161
McCutchan, F. E., 805
McDade, H., 1166
McElroy, P. D., 1678
McGeer, A., 74
McGovern, T. W., 1576
McIntyre, L., 765
McLaine, P. N., 1042
McLaughlin, M., 537
McMahon, B. J., 676
McNeil, J. G., 805
Meehan, P. M., 297
Meinders, A. E., 1057
Melcher, G. P., 837
Melnick, J. L., S2
Mencacci, A., 1279
Merigan, T. C., 177, 432, 1072, 1325
Meriwether, R. A., 1497
Meschievitz, C., 1074
Messadi, F., 1504
Metzger, D. W., 1643
Mevissen, M., 498
Meyer, W. A., III, 305
Meyer-König, U., 705
Meyers, J. D., 1545, 33
Micciolo, R., 1317
Michael, R. A., 805
Michaelsen, K. F., 506
Michels, K. R., 576
Miedema, F., 531, 811
Minelli, F., 514
Miner, D., 788
Miniter, P., 1553
Mitsuya, H., 1152, 1180
Miyamoto, T., 1455
Miyata, H., 1455
Mizokami, M., 281
Mocarski, E. S., 1599
Modaï, J., 245
Moeng, S., 451
Molgaard, C. A., 693
Molina, J.-M., 245
Monari, C., 1448
Monforte, A. D., 1603
Monroe, S. S., 1497
Montaner, J. S. G., 1438
Monteiro, G. B., 1317
Monteverde, A., 672
Monti, G., 672
Mooi, F. R., 924
Moonsammy, G. I., S53, S61
Moreau, M., 232
Mörner, A.-C., 1230
Morrey, J. D., S93
Morris, J. G., Jr., 903
Morris, S., 177, 432, 954
Morris, S. A., 493
Morse, G. D., 297
Mosci, P., 1279
Moser, C. A., 1334
Moses, A. E., 871
Moses, S., 686
Mouton, J. W., 216
Moxon, E. R., 93, 113, 1075
Moyes, D., 153
Mugerwa, R., 1066
Mughogho, G. K., 728
Mukeba, P., 503
Mulder, B., 1069
Mulder, J., 1411
Mulders, M. N., 1399
Muller, E., 220
Murcar, N., 1343
Murphy, B. R., 1107
Murphy, R., S81, 537
Murray, B. E., 1223
Murray, H. W., 992, S123, 1309
Murray, M., 1031
Murthy, N. S., 254
Musser, J. M., 871
Myers, M., 537
Nader, S., 13
Nagelkerke, N. J. D., 686
Nair, G. B., 122, 759
Nakamura, Y., 1563
Nakano, K., 425
Nash, P., 984
Natanson, S., 871
Nataro, J. P., 465, 552, 903
National Institute of Allergy and Infectious Diseases ACTG, 1628
National Institute of Allergy and Infectious Diseases Mycoses Study Group, 1675
National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group, 857
Nau, R., 948
Ndinya-Achola, J. O., 686
Ndoye, I., 1611
Ndumbe, P., 1380
Nelsing, S., 1632
Nelson, M., 1053
Nelson, S., 400, 570
Netea, M. G., 393
Neumann-Haefelin, D., 705
Nevin, T., 297
Newman, S. L., 320
Newton, D., 74
Neyts, J., 782
Ng-Bautista, C. L., 39
Ngom, P. T., 506
Ngugi, E. N., 686
Nguyen, B.-Y., 1180
Nguyen, J.-M., 232
Ngwenya, B., 515
Ni, Y.-H., 776
Niccolini, A., 514
Nicolas, F., 232
Nielsen, T. L., 1632
Nijhuis, M., 1411
Nitayaphan, S., 805
Nkengasong, J. N., 1380
Noah, T. L., 584
Nord, C. E., 1230
Noring, R., 1258
Norkrans, G., 194
Northern California Pediatric HIV Consortium, 689
Norton, C. A., 679
Novak, R. M., 68
Novick, W. J., Jr., 1628
Nugent, R. P., 1475
Nutman, T. B., 652
Nuvials, X., 472
Nuzum, E., 751
Nyambi, P., 1380
Nyole, S., 1066
Oakes, D., 1081
Obaro, S. K., 1065
O'Brien, J., 1217
O'Dempsey, T. J. D., 632
Offit, P. A., 1334
Ogundipe, J. O., 416
Ohlenbusch, A., 476
Öhman, L., 128
Ohno, T., 281
Okhuysen, P. C., 566
Okleberry, K., S93
Oksenhendler, E., 245
Oksman, P., 1060
Oldfield, E. C., III, 693, 1217
Olofsson, J., 198
Oloo, A. J., 1569
Olsen, K. D., 161
Olsvik, O., 122
Ontario Streptococcal Study Project, 74
Orenstein, J. M., 552
Orr, G. A., 493
Orrbine, E., 1042
Örtqvist, Ä., 479
Oruamabo, R. S., 1076
Osborne, B., 1545
Ossewaarde, J. M., 916
Osterholm, M. T., 679
Ottesen, E. A., 659
Otto, B. F., 290
Ottolini, M. G., 440
Ou-yang, P.-Y., 54
Oxford, J. S., 1072
Padula, S. J., 724
Pagano, P. J., 61
Pais, L. B., 632
Palaci, M., 237
Palin, K., 1514
Panigrahi, P., 903
Pankhurst, C., 515
Paoletti, E., 1623
Paoletti, L. C., 879
Paparello, S. F., 1406
Pappas, P., 1081
Para, M., 297
Pardee, A. B., 1628
Paredes, W. Y., 652
París, M. M., 161
Parker, S. J., 186
Parkinson, A. J., 1065
Parks, D. J., 1065
Parsonnet, J., 212
Partono, F., 1683
Pass, R. F., S70
Patel, R., 1010, 1014
Patterson, J. E., 1223, 1553
Patterson, T. F., 1553
Paul, J., 511
Paul, R., 508
Pavia, C., 1049

Pavlat, W. A., 1623
Pawlotsky, J.-M., 1607
Paya, C. V., 1010, 1014
Payan, C., 1615
Pellet, C., 1607
Pellett, P. E., 1351
Pennings, H.-J., 739
Peracaula, R., 472
Perera, C. U., 371
Perilli-Palmer, B., 909
Perkins, B. A., 209
Perriëns, J., 1611
Perrillo, R. P., 281
Perry, L. L., 328
Persing, D. H., 1380
Persoz, A., 1190
Pestel, M., 106
Peters, C. J., 864
Peters, H. V., 1065
Petersen, E. A., S131
Peterson, D. M., S131
Peterson, P. K., 516
Pevear, D. C., 1329
Phair, J. P., 829
Pi, D., 1034
Piaskowski, V., 1090
Piazza, F. M., 440
Picard, M., 1559
Piconi, S., 672
Piémont, Y., 607
Pieniazek, N. J., 1375
Pieper, C. F., 701
Pier, G. B., 220
Pietrella, D., 1448
Piiparinen, H., 1692
Pillot, J., 1615
Pinel, J., 879
Pinner, R. W., 1672
Piot, P., 1611
Pitha, P. M., 822
Pizzo, P. A., 761
Plikaytis, B. D., 632
Plos, K., 625
Plotkin, S. A., 26, 1690
Pluda, J. M., 1180, 1438
Plummer, F. A., 455, 686
Pocidalo, J.-J., 1070
Polianski, J., 1070
Polis, M. A., 182
Pomerantz, R. J., 190
Pönnighaus, J. M., 502
Pontieri, E., 967
Pontisso, P., 760
Pontón, J., 967
Popovic, T., 122, 765
Portaels, F., 1504
Portela, D., 1010, 1014
Portillo-Gomez, L., 954
Portner, A., 851
Powderly, W., 297
Powers, D. C., 1595
Pozio, E., 976
Pradhan, B. A., 1653
Prado, S. M. A., 1076
Preheim, L. C., 350
Prescott, L. E., 281
Presterl, E., 1078
Prévost, G., 607
Prichard, M., 546
Prince, G. A., 440
Puccetti, P., 1279
Purcell, R. H., S40, 54, 447
Purner, M. B., 984
Put, W., 1640
Qadri, F., 1653
Qian, K.-P., 281
Qian, S.-G., 54
Quindós, G., 967
Quinn, F. D., 209
Quinn, J. B., 1438
Quinn, T. C., 768
Quiroga, M., 1045
Qureshi, M. N., 190
Raab-Traub, N., 1122
Raeder, R., 1643
Raff, H. V., 1481
Rafter, D. J., 1042
Ragni, M. V., 305
Rakhmilevich, A. L., 249
Rakovsky, J., 1491
Ramadan, M. A., 483
Ramírez-Ronda, C. H., S131
Ramsay, G., 1250
Rao, M., 1653
Rappeport, J. M., 1553
Raqib, R., 376
Rasmussen, L., 177, 432
Ratto, S., 1420
Ravdin, J. I., 645
Ray, S. C., 797
Rayner, C. F. J., 113
Reddy, V. M., 68
Redfield, R. R., 1420
Redl, H., 1522
Reef, S. E., 864
Reichelderfer, P. S., 305, 1172
Reichler, M. R., 1491
Reichman, R. C., 297, 1081
Reidy, J., 190
Reinhalter, N. E., 1438
Reinholt, F. P., 1230
Resnick, L., 297
Retini, C., 1448
Reves, R., 1375
Rice, R., S53
Richard-Lenoble, D., 1384
Richie, T. L., 1678
Richman, D. D., 537, 1172
Ries, A. A., 371
Riley, L. W., 237
Rinaldi, G., 672
Ringwald, P., 1069
Rink, L., 486
Ritz, W. J., 406
Rivas, M., 1045
Rives, C. C., 1266
Rizzoni, G., 514
Robb, M. L., 805
Robbins, J. B., 1387
Roberts, C. R., 693
Roberts, G. D., 240
Roberts, M. C., 455
Roberts, P. L., 33, 717
Robertson, P., 45
Robins, T., 546
Roche, C., S44
Rockett, K. A., 1068
Rogers, R. A., 1258
Rollin, P. E., 762, 864
Roman, A., 697
Romani, L., 1279
Roos, M., 811
Roos, M. T. L., 531
Rosenkaimer, F., 992
Rosenthal, S., 1650
Rosenwaks, Z., 1657
Ross, J., 614
Ross, S. O., 1018
Rotbart, H. A., 1383
Roudot-Thoraval, F., 1607
Rougon, G., 1481
Rouse, D., 954
Rowe, P. C., 1042
Roy, M., 254
Rubin, F. A., 212
Rubin, L. G., 713
Rubin, M., 1438
Rubino, A., 976
Rübsamen-Waigmann, H., 1159
Ruderman, E. M., 362
Ruedy, J., 1438
Ruff, T. A., 290
Ruiz, J. C., 472
Runnels, J. H., 253
Rupp, M. E., 1067
Rusnak, J. M., 837
Russack, V., 782
Russell, D. A., 1528
Russo, R., 976
Rutherford, C., 1002
Ruzinski, J. T., 134
Ryan, J. L., 1159
Ryan, R., 505
Rylander, E., 1026
Saah, A. J., 829
Sabo, A., 1338
Saccardo, F., 672
Sack, D., 1653
Sack, R. B., 122, 1653
Sacks, H. S., S123, S131
Sadlon, T. A., 186
Sadoff, J. C., 1576
Safary, A., S44
Safrit, J. T., 1203
St. Sauver, J., 1660
Sakamoto, H., 1230
Sakho, L. M., 1611
Salgado, A., 472
Sällberg, M., 1356
Salo, P., 479
Salvadori, L. G., 593
Samb, B., 506
Sami, I. R., 440
Sampieri, A., 724
Samuel, M. C., 864
Sanchez, J., S53, 1074
Sánchez, J. L., 1266
Sánchez, P. J., 614
Sande, M., 897
Sanden, G., 1650
Sanders-Buell, E., 805
Sandman, L., S50
Sansano, S., 639
Santhanagopalan, V., 1289
Santosham, M., 1075
Sarfati, C., 245
Sarisky, J., 864
Sartono, E., 1683
Sauerwein, R. W., 469
Sauri, R., 472
Savarese, B., 1031
Savarino, S. J., 465
Sayles, P. C., 249
Schaasberg, W. P., 531
Schaffner, W., 1672
Schattenkerk, J. K. M. E., 1632
Schellekens, J. F. P., 916
Schellekens, P. T. A., 531
Scherer, A. M., 1420
Schießer, A., 1522
Schiff, E. R., S70
Schiffman, G., 761
Schipper, P., 1411
Schlag, G., 1522
Schleif, W. A., 1159
Schlicht, H.-J., 1461
Schlievert, P. M., 74
Schmader, K., 701
Schmitt, J. M., 1031
Schneerson, R., 1387
Schneider, C. L., 1159
Schneider, I., 1576
Schneider, M. M. E., 1632
Schoch, H. G., 1545
Schoolnik, G. K., 170, 212
Schouls, L. M., 916
Schultz, A. W., Jr., 1067
Schultz, D. R., 601
Schuurman, R., 1411
Schwartz, B., 74
Schwartz, P., 1636
Schwartz, R., S131
Scinicariello, F., 1139
Scollard, D., 400
Scott, J. D., 1295
Scroggs, R. A., 851
Seals, J., 18
Sears, C. L., 930
Secchiero, P., 273
Seck, A. M. C., 506
Sedmak, D. D., 39, 263
See, D. M., 1131
Segura, R. M., 472
Sela, S., 871
Selkon, J., 511
Semba, R. D., 1196
Séréni, D., 1190
SEROCO Study Group, 1190
Serr, A., 705
Seshamma, T., 190

Sewell, C. M., 864
Shadman, A., 1431
Shafer, R. W., 170, 1072, 1325
Shands, L. A., 864
Shapiro, E. D., 724
Shapiro, M., S40
Sharma, J. K., 254
Sharp, M., 13
Shay, L. E., 1438
Shefer, A., 1053
Sheffield, J. M., 1406
Shemer-Avni, Y., 1274
Shepardson, L., 1066
Shibayama, T., 1381
Shibl, A. M., 483
Shih, J. W., 768
Shimada, T., 122, 759
Shirasaka, T., 1152
Shirasawa, H., 425
Shiro, H., 220
Shlaes, D. M., 1646
Shlaes, J. H., 1646
Shoberg, R. J., 253
Shope, R. E., 1144
Shutsker, L., 489
Siber, G. R., 99
Sidwell, R. W., S93
Siegel, J. D., 614
Siekmann, A., 683
Sierra, M. F., 170
Sigal, L. H., 423
Sikand, V., 1371
Silberstein, G. S., 732
Siliciano, R. F., 1623
Simizu, B., 425
Simmonds, P., 45, 281
Simondon, F., 506
Sinangil, F., 1343
Singh, J. K., 406
Singh, S. P., 170
Sitz, K. V., 1420
Siwak, E. B., 1620
Sjogren, M. H., S53
Skerrett, S. J., 134
Skowron, G., S113
Slacikova, M., 1491
Slaoui, M., 1576
Slavin, M. A., 1545
Sledz, S., S123
Slemenda, S. B., 1375
Slemp, C., 1497
Smaldone, L., S118
Small, P. M., 170, 1593
Smit, F. T., 739
Smith, C. W., 342
Smith, G. E., 1595
Smith, I. L., 782
Smith, R. P., 406
Smith, T. F., 1010
Sninsky, J., 1411
Snitily, M. U., 350
Snowball, M., 676
Soares, S., 890
Sobotova, A., 1491
Söderlund, M., 710
Soewarso, T. I., 290
Sohnle, P. G., 1289
Söllberg, M., 509
Sommadossi, J.-P., S88
Sönnerborg, A., 509, 1356
Soong, C.-J. G., 645
Sordillo, E. M., 552
Soulillou, J.-P., 232
Southers, J., 1031
Spaccapelo, R., 1279
Speaker, T. J., 1334
Spear, G. T., 68
Speck, C., 1018
Spector, S. A., 537, 782, 1431
Spielman, A., 362, 476, 505, 1368
Spira, T. J., 1210
Spitalny, K. C., 356
Spritzler, J. G., 1628
Squires, K., 1431
Squires, K. E., S123
Stamm, W. E., 717, 1237
Stanat, S. C., 576
Stanbury, W. J., S44
Standaert, S. M., 1672
Stapleton, A. E., 717, 1237
Stapleton, J. T., S9
Starr, S. E., 26
Staszewski, S., 1159
Stearne-Cullen, L. E. T., 938
Steckelberg, J. M., 1223
Steephen, A., 1636
Steers, J. L., 1014
Steffen, R., S24
Steimer, K. S., 1343
Steinberg, S. M., 1152
Steinhoff, M. C., 1107
Steinmetz, H. T., 225
Stendahl, O., 128
Sterne, J. A. C., 502
Stevens, D. L., 74
Stille, W., 1159
Stockman, L., 240
Stoler, M. H., 1081
Stoll, R., 683
Storch, G. A., 1006
Straus, S. E., 1031
Strebel, P., 1650
Stringer, J. R., 1563
Stull, T. L., 204
Stuyver, L., 1607
Subianto, B., 1678
Suffys, P., 954
Sugar, A. M., 1559
Sullivan, J. L., 537
Sumiyoshi, H., 1144
Summer, W. R., 570
Summers, D. F., 845
Sundar, S., 992
Sunkin, S. M., 1563
Sutanto, A., 290
Svanborg, C., 625
Svennerholm, A. M., 1045
Switzer, W. M., 1210
Szu, S. C., 1387
Täber, M. G., 1363
Tacket, C. O., 465, 903
Taga, H., 1347
Taga, K., 1347
Tai, J. Y., 593
Tajima, K., 559
Takeda, S., 220
Takeda, Y., 759
Takezaki, T., 559
Talarico, C. L., 576
Tallman, P., 1514
Tan, T. Q., 342
Tanaka, K., 747
Tanaka, S., 1381
Tanaka, T., 1381
Tang, Y.-W., 1468
Tanowitz, H. B., 493
Tanzawa, H., 425
Tarina, P., 1491
Tartaglia, J., 1623
Tascini, C., 1448
Tatebayashi, M., 782
Täuber, M. G., 948
Tawfik, A. F., 483
Taylor, F. B., Jr., 1640
Taylor, V. I., 1159
Telford, S. R., III, 362, 505, 1368
Temesgen, Z., 240
ten Hagen, T. L. M., 385
ten Kate, M. T., 938
Tenover, F. C., 614
Terreni, M. R., 1603
Tersmette, M., 531
Tévi-Bénissan, C., 1615
Thakur, C., 751
Theodos, C., 1069
Theodos, C. M., 1302
Thiim, M., 552
Thitivichianlert, S., 805
Thomas, D. D., 253
Thomas, D. L., 768
Thomas, R. J., 693
Thomford, J. W., 505
Thompson, B., 1042
Thompson, C., 99
Thompson, J., 1107
Thompson, R. C., 1528
Thomssen, R., 476
Thonar, E. J.-M. A., 161
Tignor, G. H., 1144
Tilles, J. G., 1131
Tillotson, G. S., 728
Timpone, J., Jr., 297
Tipple, M., 489
Tisminetzky, S., 760
Titus, R. G., 1302
Todd, J., 632
Toivanen, P., 1060
Tollefson, S., 1107
Tomasz, A., 890
Tomicic, T. K., 721
Tondella, M. L. C., 209
Tong, M. J., S15
Tonnel, A. B., 743
Tonnetti, L., 1279
Torres, P.-J., 1360
Tosato, G., 1347
Tosteson, T. D., 220
Tozzi, A. E., 514
Treanor, J. J., 1595
Truitt, R. L., 1090
Trulock, E. P., 1006
Tsai, C.-C., 1338
Tsai, T., 1074
Tsakiris, L., 1607
Tsarev, S. A., 447
Tsukiyama-Kohara, K., 1381
Tubiana, R., 1166
Tucker, K. K., 1528
Tudor-Williams, G., 761
Tullus, K., 128
Tureen, J. H., 948
Turner, A. C., 502
Turner, C., 99
Turner, R. E., 864
Tuttle, J., 371
Twumasi, P. A., Jr., 632
Tzipori, S., 1069
Uehling, D. T., 462
Ueki, S. Y., 237
Uhaa, I. J., 1266
Uhl, J. R., 240
United States–People's Republic of China Study Group on Hepatitis B, 54
Urdea, M. S., 281
Vago, L., 1603
Vaheri, A., 1692
Valk, M., 811
Vancetto, M. D. C., 1076
Van Cleave, V. H., 1643
VanCott, T. C., 805
van Damme, J., 1640
van den Berg, B. M., 924
Vandenbroucke, J. P., 1057
Vandenbroucke-Grauls, C. M. J. E., 216
Van den Ende, J., 504
Van den Enden, E., 504
van der Avoort, H. G. A. M., 1399
van der Graaf, Y., 1632
van der Linden, C. J., 469
van der Meer, J. W. M., 393, 469
van der Meide, P. H., 1683
van der Poll, T., 498
van Deuren, M., 469
van Deventer, S., 229
van Dissel, J. T., 1057
van Embden, J. D. A., 916, 1504
van Furth, R., 924, 1057
van Gemen, B., 811
van Golde, L. M. G., 335
Van Gompel, A., 504
van Iwaarden, J. F., 335
van Leeuwen, R., 1166, 1411
van Loon, A. M., 1399
van Loon, F. P. L., 1653
van Soolingen, D., 1504
van Strijp, J. A. G., 335

van Vianen, W., 385
van Wijk, A., 811
Vazquez-Torres, A., 1664
Vecchiarelli, A., 1448
Vento, S., 1317
Venzon, D. J., 1180
Verbrugh, H. A., 216
Vercellotti, G. M., 576
Verdon, R., 1070
Vergara, M., 1045
Verhoef, J., 335
Vicary, C. A., 1438
Vidal, J., 1360
Villers, D., 232
Virji, M., 113
Virology Committee Resistance Working Group, 1172
Visvesvara, G., 1375
Vitek, C. R., 1022
Vlahov, D., 797, 822, 1196
Voet, P., 1576
Vogels, M. T. E., 393
Volberding, P., S79, S150
Volvovitz, F., 1595
von Briesen, H., 1159
von Laer, D., 705
Voorhees, R. E., 864
Wachsmuth, I. K., 765
Wachsmuth, K., 122
Wada, M., 1563
Wadell, G., 1026
Wagenvoort, J. H. T., 216
Wages, J., 751
Wagner, R., 1559
Wainberg, M. A., 1438
Wainwright, R., 676
Waldman, W. J., 263
Wallace, M. R., 1217
Wallace, R. J., Jr., 747
Wallaert, B., 743
Walling, D. M., 1122
Walsh, B., 511
Wan, C.-Y., 54
Wang, F., 1347
Wang, H., 85
Wang, N. E., 689
Ward, J. I., 1075
Ward, J. W., 961
Ward, W. W., 837
Warren, R. P., S93
Warthan, S. N., 1438
Wasserman, S. S., 312
Watanabe-Ohnishi, R., 74
Waterbury, J. A., 1159
Watson, A. S., 851
Weber, J., 1166
Wecksler, W., 312
Weigler, B. J., 1139
Weil, G. J., 1586
Weiland, O., 1356
Weinhold, K. J., 1623
Weir, R., 1203
Weiss, L. M., 493
Weiss, P. J., 1217
Weiss, W., S123
Weiss, W. R., 1569
Weizman, A., 1244
Welbel, S. F., 356
Welles, S., 1172
Wells, G., 1042
Wells, J. G., 122
Wenger, J. D., 765
Wenisch, C., 1078
Werner, B., 1053
Wessels, M. R., 879
Westendorp, R. G. J., 1057
Wettergren, B., 625
Wharton, M., 765, 1650
White, A. C., Jr., 253, 1071
White, F., III, 751
White, M. L., 948
Whitley, R. J., 857
Whittier, S., 890
Whittington, W. L., 455
Whittle, H., 506
Wiersma, A., 811
Wiesner, R. H., 1010, 1014
Wignall, F. S., 1678
Wijdenes, J., 469
Wiley, C. A., 782
Wilkerson, M. J., 328
Wilkinson, B. E., 1595
Williams, D. L., 240
Williams, J., 676
Wilson, C. B., 134
Wilson, M., 505
Wilson, M. H., 1107
Wilson, M. L., 1375
Wilson, R., 113
Winters, M. A., 1072
Winther, B., 1329
Wirtz, C., S118
Witham, N. D., 212
Witkin, S. S., 1657
Wittner, M., 493
Wolf, H. M., 437
Wolfe, M. S., S29
Wolff, C., 705
Wolitz, R., 177
Wong, A., 1034
Wong, D. C., S40
Wood, K., 297
Woodford, N., 511
Woodle, M. C., 938
World Health Organization Collaborative Study Group on Oral Poliovirus Vaccine, 1097
Wormser, G. P., 1379
Wortman, I. A., 584
Wouters, E. F. M., 739
Wretlind, B., 376
Wright, P. F., 1107
Wyvill, K. M., 1180
Xia, M., 455
Xu, H.-F., 54
Xu, K., 503
Xu, Z.-Y., 54
Yamaguchi, H., 1539
Yamamoto, S., 1210
Yang, Z.-P., 736
Yap-Yap, J., 1069
Yarchoan, R., 1152, 1180, 1438
Yazdanbakhsh, M., 1683
Ye, L., 566
Yeganegi, H., 1309
Yevich, S. J., 1266
Yikang, D., 465
Yousif, A., 511
Yu, X., 797
Yuan, G., 1576
Yuen, G. J., 1438
Yuhas, Y., 1244
Zabriskie, J. B., 593
Zeballos, G. A., 493
Zehender, G., 672
Zeitz, P. S., 864
Zeller, H., 506
Zenilman, J., 768, 930
Zhang, L., 1514, 1628
Zhang, L. J., 1002
Zhang, L. Q., 45
Zhang, Y., 240
Zhang, Z.-X., 1356
Zhu, Q.-R., 54
Zhuang, Y.-L., 54
Zijlstra, E. E., 498
Zimmerli, W., 639
Zipeto, D., 177
Zribi, M., 1504
Zuckerman, M., 502
Zumla, A., 1636

Subject Index

3TC, for HIV-1 infection, 1166, 1411, 1438
α acid glycoprotein, inhibition of HIV protease inhibitors, 546
α-mannosidase levels, in HIV-1 infection, 683
β-hexosaminidase, levels in HIV-1 infection, 683
β-lactams, plus glycopeptide and gentamicin, for *E. faecium* endocarditis, 106
A77003, inhibitor of HIV-1 protease, effect of serum α_1 acid glycoprotein on in vitro activity, 546
Abscess, amebic liver, subunit vaccine, gerbil model, 645
Adenovirus
  protein, binding of TNF and lymphotoxin, mouse model, 570
  T cell response, 1090
Afipia felis, vs. *Bartonella*, CSD, 916
Albendazole, for microsporidiosis, in AIDS, 245
Amphotericin B, for candidiasis, role of TNF-α in, 406
Ampicillin, for *S. aureus* endocarditis, methicillin-resistant, 897
Animal model
  adenovirus, protein, binding of TNF and lymphotoxin, mouse, 570
  bacteremia, monocyte chemotactic protein 1 release, baboon, 1640
  B. burgdorferi infection, vaccine, dog, 909, 1049
  B virus, venereal, transmission, rhesus monkey, 1139
  C. albicans killing by neutrophils, immunodeficient mouse, 1664
  CMV
    replication, interstrain differences, SCID-hu mouse, 1599
    retinitis, rabbit, 782
    vaccine, mouse, 18
  C. trachomatis lung infection, after intranasal inoculation, mouse, 736
  diabetes, virus-induced, mouse, 1131
  E. coli
    sepsis, thrombomodulin release, baboon, 1522
    UTI, induction by intraurethral inoculation, mouse, 462
  E. faecium endocarditis, antimicrobial combinations for, rabbit, 106
  E. histolytica liver abscess, vaccine, gerbil, 645
  GAS infection, skin, protection by IL-2, mouse, 1643
  HAV vaccine, marmoset, S40
  HIV-1 infection
    immunoprophylaxis, SCID mouse, 1203
    recombinant gp160, induction of Th1 memory cells, chimpanzee, 437
  H. pylori virulence, gnotobiotic piglet, 459
  L. donovani infection, IFN for, nude mouse, 1309
  Lyme disease, vaccine, mouse, 1368
  meningitis
    bacterial, ICAM-1–deficient mouse, 342
    endotoxin-induced, $rBPI_{23}$ effect in, rabbit, 948
  M. tuberculosis infection, TNFR gene transfer, mouse, 400
  pulmonary inflammatory responses, neonatal rat, 134
  rotavirus, microencapsulated, antibody in gut-associated lymphoid tissue, mouse, 1334
  RSV infection, immunoprophylaxis, 440, 1468
  S. aureus
    endocarditis, methicillin-resistant, therapy for, rabbit, 897
    osteomyelitis, hematogenous, rat, 1230
  sepsis, gram-negative, BPI in, mouse, 153
  Shigella neurologic syndromes, pathogenesis, mouse, 1244
  SIV infection, PMEA for, macaque, 1338
  S. pneumoniae phagocytosis, cirrhotic rat, 350
  toxoplasmosis, T cells, mouse, 249
Antibody to
  CD4, in HIV-1 infection, 312
  CMV
    association with intrauterine transmission, 1115
    detection in normal donor blood, 1002
  E. coli heat-labile toxin and CFAs, in children, 1045
  GAS, 593
  hantavirus, 762
  HAV, prevalence, 447, S19
  HEV, prevalence, 447
  HIV, in cervicovaginal secretions, 1615
  hsp90, in candidiasis, murine, 1668
  HSV, in encephalitis, 1692
  HTLV-I, dependence on provirus load, 1455
  pneumococcal polysaccharide vaccine and *H. influenzae* type b conjugate vaccine, in HIV-1 infection, 1217
  poliovirus, nonstructural proteins, 845
  polysialic acid, interaction with embryonal brain glycopeptides, 1481
  rotavirus, in gut-associated lymphoid tissue, mouse model, 1334
  Sin Nombre virus, 762
  tetanus toxoid, maternal and child, 1076
  T. gondii, in amniotic fluid, role, 1384
Antimony, plus IFN-γ, for visceral leishmaniasis, 992
Arthritis, suppurative, cytokine inhibitors, rabbit model, 161
Aspergillus infection, invasive, antigen detection, 1553
Atevirdine, and zidovudine, for HIV-1 infection, pharmacokinetics, 297
Atovaquone, for PCP, in HIV-1 infection, adverse effects, 1295

B19 parvovirus, IgG avidity, in serodiagnosis, 710
Babesia microti, serologic test, predictive value, 504
Bacteremia
  LPS toxicity-regulating proteins, role, 1250
  monocyte chemotactic protein 1 release, baboon model, 1640
  multiple-drug resistant, in Slovakia, 1491
  S. epidermidis, catheter-related, 220
  S. pneumoniae, in US children, 885
Bactericidal/permeability-increasing protein
  detection, by ELISA, 739
  in gram-negative sepsis, mouse model, 153
  recombinant, effect in meningitis, 948
Bacteroides species, intraamniotic infection, 1475
Bartonella species vs. *A. felis*, CSD, 916
Blastomyces dermatitidis, conidia, interactions with macrophages, 1559
Bordetella pertussis
  fimbriae, binding to human monocytes, 924
  infection, outbreak, 1053, 1650
Borrelia burgdorferi infection
  antibody, 253
  biliary complications of treatment, 356
  carditis, macrophages in, 362
  editorial, 423
  pathogenesis, 1258
  in school-aged population, 1371
  vaccine, animal models, 909, 1049, 1368
Branched DNA assay, to detect HCV RNA, 443
Brazilian purpuric fever, *H. influenzae* biogroup aegyptius, 209, 713
Brefeldin A, effect, on Shiga-like toxins, 721
Brugia malayi, filariasis, diethylcarbamazine for, IFN-γ after, 1683
B virus, venereal, transmission, rhesus monkey model, 1139

Calcivirus, gastroenteritis, oyster-associated outbreak, 1497
Calprotectin, growth-inhibiting effect, on *C. albicans*, 1289
Candida albicans
  infection
    candidacidal activity of murine neutrophils, 1664

E. coli superinfection, mortality, mouse model, 1539
gastrointestinal, Th1/Th2 responses, 1279
hsp90 in, 1668
TNF in, 393, 406
zinc-supplemented, resistance to calprotectin, 1289
Candida parapsilosis, biotype diversity, 967
Candida species
adhesion, epithelial, expression of integrin analog, 1660
fluconazole for, prophylaxis in BMT, 1545
Caprine arthritis-encephalitis virus, immune response, 328
Carditis, *B. burgdorferi*, macrophages in, 362
Cat-scratch disease, *Bartonella* species vs. *A. felis*, detection, 916
Catheter-related bacteremia, *S. epidermidis*, 220
CD14, soluble, in septic shock, 639
CD4 cell, response, against adenovirus, 1090
Ceftazidime, liposomal, for *K. pneumoniae* infection, 938
Chagas' disease, induction of endothelin release, 493
Chancroid, *see Haemophilus ducreyi* infection
Chlamydia pneumoniae, infection, ciliostasis, 1274
Chlamydia trachomatis
detection, cervical, by PCR, and in vitro fertilization outcome, 1657
infection, lung, after intranasal inoculation, mouse model, 736
Chloroquine, and primaquine, for *P. vivax* malaria, chloroquine-resistant, 1678
Cholera, summary of 29th US-Japan Joint Conference, 8
Chromosorb, for *E. coli* O157:H7 HUS, 1042
Cidofovir, for CMV infection, 788
Ciprofloxacin, for *N. meningitidis* infection, in rural Africa, 728
Cirrhosis, alcoholic liver, cytokine production in, 743
Clarithromycin, serum levels, in *M. avium-M. intracellulare* infection, 747
Coccidioides immitis infection
disseminated, in AIDS, 961
meningitis, TNF-α and IL-1β in, 1675
outbreak, in military, 1672
Colonization factor antigens, *E. coli*, antibody to, in children, 1045
Condyloma acuminatum
cryotherapy and IFN for, 1080
sequence variation in, 697
Corynebacterium diphtheriae, infection, workshop report, 765
Coxsackievirus B4, diabetes induction, 1131
Cryoglobulinemia, mixed, HCV RNA in bone marrow, 672
Cryptosporidium parvum
enteric, Caco-2 cell line model, 976
IgA, antibody response, 256
paromomycin for, in AIDS, 1070, 1071
Cytokine
in HIV-1 infection, 1628
inhibitors, in meningitis, rabbit model, 161
nasal, in respiratory infection, acute upper, 584
production, in alveolar macrophages, in alcoholic liver cirrhosis, 743
secretion, in *Shigella* infection, 376
Cytomegalovirus
antibody, detection in normal donor blood, 1002
cellular distribution, in pneumonia, 39
DNA
in CMV retinitis, PCR quantitation in HIV-1 infection, 177
detection in normal donor blood, 1002
ganciclovir resistance mutations, 576
in HIV-1 infection, in semen, 432
human, IE and late transcripts in PBL, 705
infection
cidofovir for, 788
in CNS, in AIDS, ganciclovir for, 1603
congenital, 1115
in transplant recipients, 1006, 1010
replication, interstrain differences, SCID-hu mouse model, 1599
retinitis
in HIV-1 infection, 182
rabbit model, 782
screening test, predictive value, 1688, 1689
RNA, detection in normal donor blood, 1002
shedding, 33, 1018
transmission, endothelial cell–monocyte, in vitro model, 263
vaccine response
in mice, 18
in women of child-bearing age, 26

Delavirdine, inhibition of HIV-1 in vitro, 61
Diabetes, virus-induced, mouse model, 1131
Diarrhea
chronic, in HIV-1 infection, 552
C. parvum, pathophysiology, 976
E. coli, enteroaggregative, virulence, 465
HIV-associated, HEp-2 cell–adherent *E. coli*, 1636
microsporidial, chronic, in AIDS, in Africa, 515
S. dysenteriae, antimicrobial-resistant, 371
V. cholerae O139 Bengal, infection, clinical and immunologic characteristics, 903
Didanosine, for HIV-1 infection, 305, 1152, 1180
Diethylcarbamazine, for filariasis, lymphatic, IFN-γ after, 1683
Diphtheria, diagnostic workshop report, 765

E-selectin, in endotoxemia, experimental, in humans, 145
Editorial
EBV, new insights, 1323
HIV infection, therapy, 521, 1325
Lyme disease, treatment, 423
M. tuberculosis, global migration, 1593
Ehrlichia infection, seroprevalence, in US military, 1266
Elephantiasis, in lymphatic filariasis, in Haiti, 755
ELISA for detection of
bactericidal/permeability-increasing protein, 739
HIV-1 antibody, in saliva, 1406
Lyme disease, 724
Encephalitis, HSV, diagnosis by PCR, disease correlation, 857
Encephalitozoon cuniculi, in AIDS, detection by PCR, albendazole for, 1375
Endocarditis
E. faecalis, virulence, 1223
E. faecium, β-lactam–glycopeptide–gentamicin combinations for, 106
Endothelin, role in Chagas' disease, 493
Endotoxemia
experimental, cytokines and E-selectin, in humans, 145
TNF
and IL-1 in, rat model, 1528
inhibitors in, 393
Endotoxin, neopterin and cytokine network, in septic shock, 472
Entamoeba histolytica, vaccine, 645
Enterococcus faecalis, endocarditis, virulence, 1223
Enterococcus faecium, endocarditis, β-lactam–glycopeptide–gentamicin combinations for, 106
Enteropathy, bacterial, chronic, in HIV-1 infection, 552
Epidemiology
B. pertussis infection, 1053, 1650
B virus infection, venereal, transmission, rhesus monkey model, 1139
C. immitis infection

in AIDS, in USA, 961
outbreak, in military, 1672
gastroenteritis, outbreak, oyster-associated, 1497
hantavirus pulmonary syndrome, risk factors, 864
HAV infection, S2, S19, S24, S29
HBV infection, 693, 1031
HCV infection, 768, 1034, 1607
H. ducreyi infection, in Malawi, 451
herpes zoster, racial differences, 701
HIV-1 infection
coccidiomycosis in, in USA, 961
dual, with *env* subtypes, 805
gene sequence variation, in PCR-positive seronegative IDU, 797
and genital ulcer disease, in Malawi, 451
P. aeruginosa infection in, risk factors, 930
perinatal, early recognition, 689
progression, 686, 829
vitamin A deficiency and wasting, in IDU, 1196
HPV infection
genital, among sex partners, 429
transient, in young women, 1026
H. pylori infection, effect on risk and severity of cholera, 1653
HTLV-I
seroconversion after age 40, incidence in Japan, 559
transmission, mother-to-child, in Guaymi indians, 1022
HTLV-I/II infection, transmission risk, in US marines in Okinawa, 693
K. pneumoniae infection, nosocomial and international spread, 511
Lyme disease, in school-aged population, 1371
measles, outbreak, transmission in domed stadium, 679
molecular, poliovirus, type 1, wild, 1399
M. tuberculosis, molecular epidemiology, Ethiopia, Netherlands, and Tunisia, 1504
N. meningitidis, ciprofloxacin and rifampicin for, in rural Africa, 728
P. aeruginosa, infection, in AIDS, risk factors, 930
P. falciparum malaria, in refugees, risk reduction, 489
Rickettsia and *Ehrlichia* infections, in US military, 1266
S. aureus
methicillin-resistant, eradication from neonatal ICU, 614
nasal carriage, risk factor for cardiac surgical infection, 216
S. dysenteriae, antimicrobial-resistant, in Zambia, epidemic, 371
S. pneumoniae infection
invasive, 1065
multiple-drug resistance, in Slovakia, 1491
penicillin-resistant, in day care, 890
serotype distribution, in US children, 885
T. pallidum infection, congenital, in New York, 732
tuberculosis, multidrug-resistant, in New York City, 170
V. cholerae O139 infection
molecular subtyping, in India and Bangladesh, 122
spread, in India, 759
W. bancrofti, lymphatic filariasis, in Haiti, 755
Epstein-Barr virus
editorial, new insights, 1323
mononucleosis, IL-10 for, 1347
oral hairy leukoplakia, 1122
Errata
Adler et al., 1995;171:26–32, 1080
Nosten et al., 1994;170:971–7, 519
Escherichia coli
colonization, rectal and vaginal, in recurrent UTI, 717
enteroaggregative, virulence, 465
heat-labile toxin and CFAs, antibody to, in children, 1045
HEp-2 cell–adherent, in HIV-associated diarrhea, 1636
infection
in candida-infected mice, mortality, 1539
O103, anti-LPS antibody in HUS, 514
O157:H7, HUS, chromosorb for, 1042
sepsis, thrombomodulin release, baboon model, 1522
septicemia, neonatal, interaction with neutrophils, 128
UTI, 462, 625, 1514
Exanthem subitum, HHV-6 viremia, 273

Filariasis
diethylcarbamazine for, IFN-γ after, 1683
W. bancrofti, 755, 997
Fimbriae, *B. pertussis*, binding to human monocytes, 924
Flagellar serotypes, *S. typhi*, 212
Fluconazole
for candidiasis, TNF-α role in, 406
prophylaxis after BMT, 1545
Foscarnet, for HSV infection, acyclovir-resistant, 508
Friend virus, infection, IFN-α and stavudine for, S93
Fusion protein, parainfluenza virus type 1, evolution, 851

Ganciclovir
for CMV infection, of CNS, in AIDS, 1603
for HIV-1 infection, 1431
resistance, due to CMV UL97 phosphotransferase mutation, 576
Gardnerella vaginalis, intraamniotic infection, 1475
Gastroenteritis, oyster-associated, epidemiology, 1497
Gentamicin, liposomal, for *K. pneumoniae* infection, 938
Glucocorticoids, for HIV-1 infection, for CD4 cell count, 523
Gonorrhea, *see Neisseria gonorrhoeae* infection
Gram-negative septic shock, soluble CD14 in, 639
Granulocyte colony-stimulating factor, effect on PMNL fungicidal activity, in AIDS, 1448
Granulocyte, inflammatory mediator release, *S. aureus* leukocidin effect on, 607
Group A streptococci
antibody, carbohydrate, opsonophagocytic properties, 593
fibrinogen, role in plasminogen acquisition, 85
fibronectin binding, M type distribution, 871
infection
invasive, and TSS, 74
skin, protection by IL-2, mouse model, 1643
vaccine, 1038
Group B streptococci type V
infection, emergence, 513
vaccine, 879
Group G streptococci, M proteins, resistance to phagocytosis, 601

Haemophilus ducreyi, infection, and HIV-1 control, in Malawi, 451
Haemophilus influenzae biogroup aegyptius
145-kDa protein, phase-variable expression, 713
Brazilian purpuric fever, 209
meningitis, ICAM-1–deficient mouse model, 342
type b, vaccine, 93, 99, 1075
Halofantrine, for *P. vivax* malaria, chloroquine-resistant, 1678
Hantavirus
antibody to, 762
pulmonary syndrome, risk factors, 864
Heat-shock protein 90, in candidiasis, mouse model, 1668
Helicobacter pylori infection
effect on risk and severity of cholera, 1653
virulence, gnotobiotic piglet model, 459
Hemagglutination, by *Lactobacillus* species, vaginal, 1237
Hemolytic uremic syndrome

E. coli O103, anti-LPS antibody in, 514
E. coli O157:H7, chromosorb for, 1042
Hepatitis A virus
epidemiology, S2
and HEV, antibody prevalence, in India, 447
history, S2
infection
manifestations, clinical, community hospital, S15
response, immune, S9
seroepidemiology, S19
in travelers, European, S24
vaccine
control strategy, in USA, S73
and HBV vaccine, administration routes, S53
inactivated, 676, S33, S40, S44, S50, S61, S70
Hepatitis B virus
infection, perinatal, postexposure immunization, 54
mutant, precore, 194, 776, 1461
vaccine, infant project, in Indonesia, 290
Hepatitis C virus
genotypes
in Cameroon, 1380
clinical correlations, 760
in hospitalized patients, 1034
sources of infection, 1607
infection
acute vs. chronic, by site-directed serology, 1356
chronic, genotypes, 281, 1381
transmission, sexual, 768
RNA
bDNA assay and genotyping, 443
in bone marrow, in mixed cryoglobulinemia, 672
Hepatitis E virus, and HAV, antibody prevalence, in India, 447
Herpes B virus, infection, seroprevalence, in primate handlers, 1031
Herpes simplex virus infection
disseminated, acyclovir-resistant, foscarnet for, 508
encephalitis
antibody production in, 1692
diagnosis by PCR, disease correlation, 857
Herpes zoster, racial differences, 701
Histoplasma capsulatum, macrophage function, in AIDS, 320
HPMPC, for CMV infection, 788
Human herpesvirus 6
detection, by PCR, in children, 273
in PBMC of S100-positive, T cell chronic lymphoproliferative disease, 1351
Human immunodeficiency virus type 1
CD4 lymphocyte lines, envelope-specific, 1420
HIV-1 protease inhibitor (A77003), effect of serum α_1 acid glycoprotein, 546
infection
3TC for, 1438
β-hexosaminidase and α-mannosidase levels in, 683
antibody, 312, 1406
asymptomatic, T cell function as marker of progression, 531
atevirdine and zidovudine for, 297
CD4 cell count, glucocorticoids for, 523
CD4 cell lines, 1420
clinical aspects and treatment rationale, S81
clinical trials, editorial, 1325
CMV infection, 177, 182, 432, 1603
coccidiomycosis in, 961
cryptosporidiosis in, paromomycin for, 1070, 1071
detection of RT in sera, 1210
diarrhea in, 515, 1636
didanosine for, long-term therapy, 1180
dual, with *env* subtypes, 805
enteropathy, chronic bacterial, 552
epidemiology, molecular, 45
ganciclovir for, 1431
G-CSF role in PMNL fungicidal activity, 1448
gene sequence variation, in PCR-positive seronegative IDU, 797
and genital ulcer disease, in Malawi, 451
IFN-α resistance of primary isolates, 822
immunoprophylaxis, SCID mouse model, 1203
lamivudine for, 1166, 1438
in leprosy, 502, 503
macrophages, activity against *H. capsulatum*, 320
and *M. avium*, coinfection, 68
microsporidiosis in, albendazole for, 245
neurologic manifestations of progression, 1190
nevirapine for, 537
nucleoside therapy, pharmacokinetics, S99
oral mucosal cells, 190
p24 antigen, in cervicovaginal secretions, 1615
P. aeruginosa infection in, risk factors, 930
P. carinii pneumonia, TMP-SMZ for, 1295, 1632
pediatric, *S. pneumoniae* pneumonia and bacteremia in, 761
pentoxifylline for, 1628
perinatal, early recognition, 689
progression, 686, 811, 829, 837
quantitative cell microculture, measure of efficacy, 305
recombinant gp160, induction of Th1 memory cells, chimpanzee model, 437
resistant, antiviral therapy, S140
response to pneumococcal polysaccharide vaccine and *H. influenzae* type b conjugate vaccine, 1217
RNA load, resistance to lamivudine, 1411
shedding, seminal, 1018
single-strand conformational polymorphism analysis, 1619
stavudine for, S79, S88, S113, S118, S123, S131
treatment, 521, S79, S150
V3 loop antibodies in, 509
vaccine, 1343
viremia change, drug-related mutations, 1152
vitamin A deficiency and wasting, predictors in IDU, 1196
zidovudine for, 1152, 1159, 1172
inhibition, in vitro, by delavirdine with protease inhibitor or IFN-α, 61
RNA, reverse transcription, method, 1072
vaccine against, CTL response, 1623
Human papillomavirus
and cancer, esophageal, in Japan, 425
infection
genital, among sex partners, 429
and pregnancy, 254
transient, in young women, 1026
sequence variation, in long control region, 697
Human T cell lymphotropic virus type I
antibody
dependence on provirus load, 1455
seroconversion after age 40, in Japan, 559
transmission, mother-to-child, 1022
Hydrocele, in lymphatic filariasis, in Haiti, 755
Hypothesis, IgG, protective immunity, 1387

IgA, response, after Norwalk virus infection, 566
IgG

avidity in parvovirus B19 serodiagnosis, 710
protective immunity, hypothesis, 1387
Influenza A virus
interaction with surfactant protein A, 335
vaccine
IgA antibody, 1072
recombinant hemagglutinin, 1595
response, systemic and local, 198
In situ hybridization, to localize rhinovirus, in upper respiratory tract, 1329
Intercellular adhesion molecule-1, in meningitis, mouse model, 342
Interferon-α
for condyloma acuminatum, 1080
inhibition of HIV-1 in vitro, 61
resistance, by HIV-1 primary isolates, 822
with stavudine, for Friend virus infection, S93
Interferon-γ
and antimony, for visceral leishmaniasis, 992
for *L. donovani* infection, 1302, 1309
and MTPPE, for *K. pneumoniae* septicemia, 385
Interleukin, human, for DA1.a cells/leukemia inhibitory factor, in sepsis, 232
Interleukin-1
receptor antagonist, in meningitis and arthritis, rabbit model, 161
and TNF, endotoxemia, rat model, 1528
Interleukin-1β, in *C. immitis* meningitis, 1675
Interleukin-2, in GAS skin infection, 1643
Interleukin-6
in granulocytopenia, after myelotoxic chemotherapy, 225
and monocyte/macrophage-induced inflammatory response, 472
in sepsis, 469
Interleukin-10
for EBV-induced mononucleosis, 1347
in fulminant meningococcal septic shock, 229
Isoniazid, resistance, in tuberculosis, 237, 240

Japanese encephalitis virus
attenuated, characterization, 1144
vaccine, antibody persistence, 1074

Kala-azar, antimony plus IFN-γ for, 992 (*See also* leishmaniasis, visceral)
Keratin, human, homologous to *O. volvulus* antigen, 1586
Klebsiella pneumoniae infection
multiantibiotic-resistant, 511
pneumonia, liposomal gentamicin or ceftazidime for, 938
septicemia, modulation of nonspecific resistance, 385
TNF for, 393

L697661, and zidovudine, for HIV-1 infection, 1159
Lactobacillus species, vaginal, adherence, 1237
Lamivudine, for HIV-1 infection, 1166, 1411, 1438
Leishmania donovani, infection, IFN for, 1302, 1309
Leishmaniasis, visceral
antimony plus IFN-γ for, 992
diagnosis, by PCR, 751
IFN-γ for, 1302, 1309
sTNFR as markers of disease activity, 498
Lentivirus-induced arthritis, immune response to viral antigen, 328
Leprosy, in HIV infection, 502, 503
Leukocidin, *S. aureus*, effect on inflammatory mediator release, 607
Lipopolysaccharide
antibody, in *E. coli* O103 HUS, 514
effects in lung, neonatal rat model, 134
in neurologic syndromes, mouse model, 1244
toxicity-regulating proteins, in bacteremia, 1250
zinc effect on, 486
Liver transplantation
CMV detection in, techniques, 1010
CMV infection in, OKT3 treatment for allograft rejection, 1014
L-selectin, in *P. falciparum* malaria, 1078
Lung transplantation, CMV viremia in, quantitative analysis, 1006
Lyme disease
biliary complications of treatment, 356
diagnosis, by rOspC ELISA, 724
immunity, protective, 253
pathogenesis, 1258
in school-aged population, prospective assessment, 1371
spirochetes, *OspA* genetic variation, 476
therapy for, duration, 1379, 1380
vaccine, animal models, 909, 1368

Macrophage
alveolar, cytokine production, in liver cirrhosis, 743
in HIV-1 infection, activity against *H. capsulatum*, 320
in Lyme carditis, 362
Malaria
cerebral, NO in, 1068, 1069
P. falciparum
L-selectin in, 1078
pentoxifylline for, in children, 1317
in refugees, risk reduction, 489
in pregnancy, mefloquine prophylaxis, 253
Measles
outbreak, transmission in domed stadium, 679
vaccine, Edmonston-Zagreb, high-titer, in Senegal, 506
Mefloquine, prophylaxis for malaria, in pregnancy, 253
Menfegol, genital lesions due to, 1611
Meningitis
bacterial, cytokine inhibitors, rabbit model, 161
C. immitis, TNF-α and IL-1β in, 1675
endotoxin-induced, $rBPI_{23}$ effect in, rabbit model, 948
H. influenzae and *S. pneumoniae*, ICAM-1–deficient mouse model, 342
meningococcal, polysaccharide-protein vaccine, 632
multiple-drug resistance, in Slovakia, 1491
N. meningitidis group B and *E. coli* K1, vaccination against, 1481
S. pneumoniae, in US children, 885
Methicillin, resistance in *S. aureus*, teicoplanin susceptibility, 1646
Microsporidiosis, in AIDS, 515, 1375
Monoclonal antibody, as immunoprophylaxis for HIV-1 infection, 1203
Monocyte, CMV infection, 263
Monocyte/macrophage, inflammatory response, in septic shock, 472
Mononucleosis, EBV-induced, IL-10 for, 1347
M protein, group G streptococcus, resistance to phagocytosis, 601
M types, *S. pyogenes*, fibronectin binding, 871
Muramic acid, in PBL of healthy humans, 1060
Mycobacterium avium, and HIV-1, coinfection, 68
Mycobacterium avium–M. intracellulare, infection, clarithromycin, serum levels in, 747
Mycobacterium tuberculosis
catalase expression, 237
infection
global migration, editorial, 1593
epidemiology, molecular, in Ethiopia, Netherlands, and Tunisia, 1504
multidrug-resistant, in New York City, 170
resistance, isoniazid, 237, 240

skin test comparison, 1066, 1067
TNFR gene transfer, mouse model, 400
resistance, multiple drug, molecular mechanisms, 954
Mycoplasma arthritidis–derived superantigen, zinc effect on, 486
Mycoplasma hominis, intraamniotic infection, 1475

Neisseria gonorrhoeae, PFGE for genomic analysis, 455
Neisseria meningitidis
group B, and *E. coli* K1, vaccination against, 1481
infection
ciprofloxacin and rifampicin for, in rural Africa, 728
meningitis, $rBPI_{23}$ effect in, rabbit model, 948
TNF release in, 1057
pili, epithelial interaction effect, 113
septic shock, IL-10 levels, 229
Neutrophil
in *E. coli* septicemia, 128
recruitment, intrapulmonary, neonatal rat model, 134
Nevirapine, for HIV-1 infection, high-dose, 537
Nitric oxide
in cerebral malaria, 1068, 1069
production by human astrocytes, effect on *T. gondii* multiplication, 516
NK cells, complement-mediated lysis, 186
Norwalk-like viruses, oyster-associated, outbreak, 1497
Norwalk virus, shedding and fecal IgA response, 566

OKT3, for CMV disease in liver transplantation, 1014
Onchocerca volvulus
antigen, cross-reactive with keratin, 1586
immune response and pathogenesis, review, 659
immunity, 652
Oral hairy leukoplakia, EBV coinfection and recombination, 1122
Osteomyelitis, hematogenous, rat model, 1230
Otitis media
resistance, multiple-drug, in Slovakia, 1491
S. pneumoniae, in US children, 885

p24 antibody, in HIV-1 infection, as predictor of progression, 811
Papillomavirus, human
and esophageal cancer, in Japan, 425
and pregnancy, 254
sequence variation, in long control region, 697
Parainfluenza virus
type 1, F glycoprotein, evolution, 851
vaccine, live attenuated, in infants and children, 1107
Paromomycin, for cryptosporidiosis, in AIDS, 1070, 1071
Parvovirus B19 infection
IgG avidity, in serodiagnosis, 710
in pregnancy, perinatal outcome, 1360
Pentoxifylline for
HIV-1 infection, 1628
P. falciparum malaria, cerebral, in children, 1317
Phagocytosis, *S. pneumoniae*, cirrhotic rat model, 350
Pili, *N. meningitidis*, epithelial interaction effect, 113
Plasminogen
acquisition, by GAS, 85
binding, to *B. burgdorferi*, 1258
Plasmodium falciparum malaria
cerebral, pentoxifylline for, in children, 1317
L-selectin in, 1078
NO in, 1068, 1069
prophylaxis
mefloquine, in pregnancy, 253
primaquine, comparison with other drugs, 1569
in refugees, risk reduction, 489
vaccine, safety, immunogenicity, and efficacy, 1576
Plasmodium vivax, chloroquine-resistant, chloroquine and primaquine or halofantrine for, 1678
PMEA, for chronic SIV infection, macaque model, 1338
Pneumocystis carinii
antigenic variation, surface glycoprotein genes, 1563
pneumonia in HIV-1 infection, TMP-SMZ for, 1295, 1632
Pneumonia
CMV, secondary immunosuppression in, 39
K. pneumoniae, liposomal gentamicin or ceftazidime for, 938
P. carinii, in HIV-1 infection, TMP-SMZ for, 1295, 1632
Pneumovax vaccine, in HIV-1 infection, 761
Poliovirus
nonstructural proteins, antibody response, 845
vaccine, oral, immunogenicity, 1097
wild, type 1, molecular epidemiology, 1399
Polymerase chain reaction to detect
Bartonella vs. *A. felis* DNA, 916
B virus, 1139
CMV, in HIV infection, 177, 1603
C. trachomatis, in cervices of culture-negative women, 1657
E. cuniculi, in AIDS, 1375
HBV precore TAG mutant, restriction site method, 194
HCV, 776, 1034
HHV-6, in children, 273
HIV, 190, 312, 797
HPV DNA, 425
HSV, 857, 1692
HTLV-I, 1455
Leishmania, 751
pneumococcal toxin protein, 479
ribotyping, for molecular epidemiology, 204
RT, 1172, 1210
Pregnancy
infection, intraamniotic, genital flora, 1475
parvovirus B19 infection in, perinatal outcome, 1360
Primaquine, prophylaxis for *P. falciparum* malaria, vs. other antiparasite drugs, 1569
Protease inhibition (U-75875), inhibition of HIV-1 in vitro, 61
Pseudomonas aeruginosa, infection, in AIDS, risk factors, 930
Pulsed-field gel electrophoresis to type
C. parapsilosis, 967
N. gonorrhoeae, 455
S. aureus, 614

Quantitative cell microculture, of HIV-1, as measure of antiviral efficacy, 305
Quinolones, effect on urea-splitting bacteria, 483

Respiratory infection, acute upper, nasal cytokines in, 584
Respiratory syncytial virus infection
immune responses, 1
immunoprophylaxis, mouse model, 1468
nasal, immunoprophylaxis, in cotton rat model, 440
Retinitis due to CMV
in HIV-1 infection, 177, 182
rabbit model, 782
screening test, predictive value, 1688, 1689
Reverse transcriptase, detection in HIV-1 infection, 1210
Review, onchocerciasis, immune response and pathogenesis, 659

Rhinovirus, human, replication in upper respiratory tract, localization by in situ hybridization, 1329
Rickettsia infection, seroprevalence, in US military, 1266
Rifampicin, for *N. meningitidis* infection, in rural Africa, 728
Rifampin, for *S. aureus* endocarditis, methicillin-resistant, 897
RNA copy number, in HIV-1 infection, progression, predictor, 811
Rotavirus, microencapsulated, antibody in gut-associated lymphoid tissue, mouse model, 1334
Rubella, vaccine, complications, 1690, 1691

Salmonella typhi, flagellar serotypes, and clinical illness, 212
Schistosoma haematobium, infection, IgE and IgG4 induction in, 416
Sepsis
  gram-negative, BPI in, mouse model, 153
  HILDA/LIF levels in, 232
  IL-6 levels and granulocytopenia, after myelotoxic chemotherapy, 225
  IL-6 receptor in, 469
Septata intestinalis, infection, in AIDS, albendazole for, 245
Septic shock
  N. meningitidis, IL-10 levels, 229
  soluble CD14 in, 639
  TNF and IL-1, in endotoxemia, rat model, 1528
Septicemia, *E. coli*, neonatal, host susceptibility, 128
Shiga-like toxins, Brefeldin A effect, 721
Shigella dysenteriae, epidemic, antimicrobial-resistant, 371
Shigella infection
  cytokine secretion in, 376
  neurologic syndromes, pathogenesis, mouse model, 1244
Simian immunodeficiency virus, infection, PMEA for, macaque model, 1338
Single-strand conformational polymorphism analysis, of HIV-1, 1619
Sin nombre virus, antibody to, 762
Spermicide, menfegol, genital lesions due to, 1611
Staphylococcal enterotoxins, zinc effect on, 486
Staphylococcus aureus
  endocarditis, methicillin-resistant, combination therapy for, rabbit model, 897
  leukocidins, effect on inflammatory mediator release, 607
  methicillin-resistant
    eradication from neonatal ICU, 614
    teicoplanin susceptibility, 1646
  nasal carriage, risk factor for cardiac surgical infection, 216
  osteomyelitis, hematogenous, rat model, 1230
Staphylococcus epidermidis, bacteremia, catheter-related, 220
Stavudine for
  Friend virus infection, with IFN-α, S93
  HIV-1 infection, S79, S88, S113, S118, S123, S131
Streptococcal toxic shock syndrome, T cell receptors in, 74
Streptococcus agalactiae, type V vaccine, 879
Streptococcus
  group A
    antibody, carbohydrate, opsonophagocytic properties, 593
    infection, skin, protection by IL-2, mouse model, 1643
  group B, serotype V, emergence of infection, 513
  group G, M proteins, resistance to phagocytosis, 601
Streptococcus pneumoniae infection
  invasive, 1065
  meningitis, ICAM-1–deficient mouse model, 342
  multiple-drug resistance, in Slovakia, 1491
  neurotoxicity, in vitro, 1363
  penicillin-resistant, serotype transformation, 890
  phagocytosis, cirrhotic rat model, 350
  pneumonia
    and bacteremia, in HIV-infected child, 761
    diagnosis by PCR, 479
  serotype distribution, in US children, 885
Streptococcus pyogenes, fibronectin binding, M type distribution, 871
Sulbactam, for *S. aureus* endocarditis, methicillin-resistant, 897

T cell function, in HIV-1 infection, as marker of progression, 531
Teicoplanin, susceptibility, in MRSA, 1646
Tetanus, neonatal, after maternal immunization, 1076
T helper cells in
  candidiasis, gastrointestinal, 1279
  onchocerciasis, 652
Thrombomodulin, release, in *E. coli* sepsis, baboon model, 1522
Toxoplasma gondii infection
  astrocyte role, in inhibition of multiplication, 516
  diagnosis, prenatal, 1384
  immunity, cellular, in humans, 984
  primary, T cells, mouse model, 249
Trimethoprim-sulfamethoxazole for PCP
  adverse effects, 1295
  as prophylaxis, 1632
Trypanosoma cruzi, induction of endothelin release, 493
Tuberculosis
  isoniazid resistance, 237, 240
  molecular epidemiology, Ethiopia, Netherlands, and Tunisia, 1504
  multidrug-resistant, epidemiology, in New York City, 170 (*See also Mycobacterium tuberculosis* infection)
Tumor necrosis factor
  binding by adenovirus protein, mouse model, 570
  in endotoxemia, 393
  in HIV-1 infection, 1628
  and IL-1, in endotoxemia, rat model, 1528
  receptor gene transfer, in tuberculosis, mouse model, 400
  receptor, soluble
    in leishmaniasis, 498
    in meningitis and arthritis, 161
  release, in *N. meningitidis* infection, 1057
Tumor necrosis factor-α
  in candidiasis, effect of antifungals on, 406
  in *C. immitis* meningitis, 1675

Urinary tract infection
  E. coli, 462, 625, 717, 1514
  urea-splitting bacteria, 483
Urokinase, binding to *B. burgdorferi*, 1258

Vaccine against
  B. burgdorferi, 909, 1049, 1368
  CMV, immunity in women of child-bearing age, 26
  E. histolytica, 645
  GAS, 1038
  GBS V type, 879
  HAV, S24, S29, S33, S40, S44, S50, S53, S61, S73, 676
  HBV, 290, S53
  HIV-1, 1343, 1623
  H. influenzae type b, 93, 99, 1075
  influenza virus, 198, 1072, 1595
  JEV, antibody persistence, 1074
  measles, Edmonston-Zagreb, high-titer, 506
  N. meningitidis
    conjugate, 632
    group B and *E. coli* K1, 1481
  parainfluenza virus, live attenuated, in infants and children, 1107
  P. falciparum, safety, immunogenicity, and efficacy, 1576

pneumococcal polysaccharide, in HIV-1 infection, 1217
poliovirus, oral, immunogenicity, 1097
RSV, 1
rubella, complications, 1690, 1691
T. gondii, 984
VZV, cell-mediated immunity after, 13
Vaccine, protective immunity, hypothesis, 1387
Varicella-zoster virus infection
immune response, after acyclovir for childhood varicella, 1383
vaccine, live attenuated, cell-mediated immunity, 13
Vibrio cholerae infection
O1, *H. pylori* infection, effect on risk and severity of cholera, 1653
O139
characteristics, clinical and immunologic, 903
epidemiology, molecular subtyping, 122
in India, 759
summary of 29th US-Japan Joint Conference, 8
Vitamin A deficiency, in HIV-1 infection, in IDU, 1196

Western blot, to detect HIV-1 antibody, in saliva, 1406
Wucheria bancrofti, filariasis, 755, 997

Yeast, epithelial adhesion, expression of integrin analog, 1660

Zidovudine for HIV-1 infection
and atevirdine, 297
and didanosine, 305, 1180
and L697661, 1159
mutations
drug-related, and viremia changes, 1152
resistance, 1172, S140
Zinc, effect on leukocyte stimulation, 486